Skip to content

Category Archives: Anticoagulant Therapy

Regulation of Hemostasis


Key events that initiate and propagate coagulation are the redistribution of negatively charged phospholipids to the cell surface and the exposure of tissue factor to the blood. The appropriate negatively charged phospholipids, primarily phosphatidylserine, can arise as a result of either cellular activation with strong agonists like thrombin together with collagen in the case of […]

Some Critical Notices Should Knowing When Using Warfarin


PT/INR and Anticoagulation Status For the vast majority of patients        , monitoring is done using the prothrombin time with international normalized ratio (PT/INR), which reflects the degree of anticoagulation due to depletion of vitamin K-dependent coagulation. However, attention must be paid that the PT/INR in a patient on warfarin may note reflect the total anticoagulation status […]

The Management of Disseminated Intravascular Coagulation (DIC)


Disseminated intravascular coagulation (DIC) is characterized by systemic activation of blood coagulation, which results in generation and deposition of fibrin, leading to microvascular thrombi in various organs and contributing to multiple organ dysfunction syndrome (MODS). Consumption and subsequent exhaustion of coagulation proteins and platelets may induce severe bleeding. The International Society on Thrombosis and Haemostasis […]

Nine agents in one Rx. and twenty drug interactions found (Not finished)


This afternoon I met a perscription that consist of nine different agents, which have twenty drug interactions. Many of them are cardiovascular drugs. They are  Beta-Blockers, Electrolytes, Statins, ARBs, Inotropic Agents, Thiazide, Calcium Channel Blockers, and Benzodiazepines. I list them and their dosage below. Alprazolam 0.4 mg po Qd Metoprolol 12.5 mg po Bid Potassium […]

Food and drug interactions with emerging oral anticoagulants


By Michael O’Riordan June 8, 2010 (Maywood, Illinois) — A new review warns physicians to be aware of the potential for drug and dietary interactions with the emerging oral anticoagulants [1]. At present, there are few documented interactions with the new drugs, including dabigatran (Pradaxa, Boehringer Ingelheim), rivaroxaban (Xarelto, Johnson & Johnson), and apixaban (Bristol-Myers […]